Nectar Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 02, 2026.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences' board, meeting on March 2, 2026, approved two main items. First, the company will acquire 100% of Avensis Exports Private Limited (AEPL), a real estate company incorporated in 2007, for Rs. 24.96 lakhs in cash (buying 80,000 shares at Rs. 31.20 each). AEPL currently has no turnover but holds land and real estate collaborations, which Nectar plans to use to enter and grow in the real estate business as a diversification move. The deal is not a related-party transaction and is expected to close within a month. Second, the company is changing its Registrar and Share Transfer Agent from KFin Technologies to Alankit Assignments to lower costs and improve investor service; the switch will happen after data and connectivity migration are completed.
This is a small, non-material acquisition (around Rs. 25 lakhs) and a strategic diversification into real estate, away from Nectar's core pharma/life sciences business. Shareholders should watch for further details on funding, valuation of AEPL's assets, and whether this signals a larger real estate push. The RTA change is routine and should have no material effect on shareholders, though investors may need to update RTA-related records once the migration date is announced.